Document Detail


The role of comorbidities in cardioprotection.
MedLine Citation:
PMID:  21821527     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardioprotective strategies such as pre- and postconditioning result in a robust reduction in infarct size in young, healthy male animals. However, there are data suggesting that the protection is diminished in animals with comorbidities such as hypertension, hypercholesterolemia, and diabetes. It is important to understand at a mechanistic level the reasons for these differences. The effects of sex and diseases need to be considered in design of cardioprotective interventions in animal studies and clinical trials.
Authors:
Michael N Sack; Elizabeth Murphy
Related Documents :
9213357 - Inhibition of insulin release by intraduodenally infused enterostatin-vpdpr in rats.
8288157 - Effects of glucose load on brain extracellular lactate concentration in conscious rats ...
395087 - Development of a closed-loop artificial pancreas.
17425237 - New technology, new errors: how to prime an upgrade of an insulin infusion pump.
12074347 - Raising lipids acutely reduces baroreflex sensitivity.
22716997 - Comparative vascular responses three months after paclitaxel and everolimus-eluting ste...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural; Review    
Journal Detail:
Title:  Journal of cardiovascular pharmacology and therapeutics     Volume:  16     ISSN:  1940-4034     ISO Abbreviation:  J. Cardiovasc. Pharmacol. Ther.     Publication Date:    2011 Sep-Dec
Date Detail:
Created Date:  2011-08-08     Completed Date:  2012-02-13     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  9602617     Medline TA:  J Cardiovasc Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  267-72     Citation Subset:  IM    
Affiliation:
Center for Molecular Medicine, NHLBI, NIH, Bethesda, MD, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cardiotonic Agents / therapeutic use
Clinical Trials as Topic
Comorbidity*
Deafness / epidemiology,  physiopathology
Diabetes Mellitus, Type 2 / epidemiology,  physiopathology
Disease Models, Animal
Humans
Hypercholesterolemia / epidemiology,  physiopathology
Hypertension / epidemiology,  physiopathology
Ischemic Preconditioning, Myocardial / methods*
Male
Myocardial Reperfusion Injury / epidemiology*,  physiopathology*,  prevention & control,  therapy
Obesity / epidemiology,  physiopathology
Sex Factors
Grant Support
ID/Acronym/Agency:
ZIA HL002065-04/HL/NHLBI NIH HHS; ZIA HL002066-04/HL/NHLBI NIH HHS; ZIA HL005102-07/HL/NHLBI NIH HHS; ZIA HL006059-02/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Cardiotonic Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Perconditioning and postconditioning: current knowledge, knowledge gaps, barriers to adoption, and f...
Next Document:  Is It Time to Translate Ischemic Preconditioning's Mechanism of Cardioprotection into Clinical Pract...